June 20, 2017
Sponsored by

Beyond IHC: An RNAseq-based Immune Report Card to Personalize Cancer Immunotherapy


Professor and Chair of the Department of Medicine, Roswell Park Cancer Institute

Assistant Professor, Cell Biology Research, Radiation Oncology, Weill Cornell Medical College

Founder and Chief Scientific Officer, OmniSeq

This webinar discusses RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.

Recent progress in our understanding of the complex conditions required to activate a therapeutically relevant tumor-targeting immune response revealed several challenges in personalizing cancer immunotherapy. Currently, patient selection for standalone PD-1 checkpoint inhibition relies on the assessment of PD-L1 expression levels by IHC, which does not provide satisfactory stratification.

In this webinar, speakers from Roswell Park Cancer Institute, Weill Cornell Medical College, and OmniSeq provide an overview on the fundamentals of cancer immunotherapy and demonstrate that RNAseq offers a superior alternative to IHC for simultaneously measuring multiple immunological markers towards improved patient selection.

The presentations include several cases of patients treated with checkpoint inhibitors at Roswell Park Cancer Institute.

Sponsored by

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.

Sponsored by

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.